UNITY Biotechnology Announces Completion of UBX1967

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
57
UNITY Biotechnology Announces Completion of UBX1967 License and Advance into IND-Enabling Studies for Age-Related Diseases of the Eye

SAN FRANCISCO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend human healthspan by slowing, halting or reversing diseases of aging, today announced it has selected UBX1967 as the lead development candidate in the ophthalmology pipeline for advancement into studies to enable an Investigational New Drug (IND) application and executed the compound license agreement for the compound with Ascentage Pharma Group Corp Limited (“Ascentage Pharma”) under a previously agreed compound library agreement. UBX1967 is being evaluated in a range of age-related diseases of the eye, including neovascular age-related macular degeneration, proliferative diabetic retinopathy and diabetic macular edema. UNITY plans to file an IND application for UBX1967 in the second half of 2019.

“UBX1967 represents a novel approach to treating age-related eye diseases, potentially eliminating the source of multiple disease-causing factors,” said Dan Marquess, D. Phil., chief scientific officer at UNITY. “We are excited to move this program into IND-enabling studies with the goal of filing an IND in the second half of 2019 and pursuing multiple age-related eye indications in the clinic.”

About UBX1967 UBX1967, a potent senolytic small molecule inhibitor of particular members of the Bcl-2 family of apoptosis regulatory proteins, targets proteins senescent cells rely on for survival. UNITY entered into a license agreement with Ascentage Pharma granting UNITY the exclusive worldwide development and commercialization rights and non-exclusive manufacturing rights outside of Greater China (China, Hong Kong, Macau and Taiwan) for UBX1967 in all non-oncology indications. Inside Greater China, UNITY is obligated to commercialize UBX1967 through a joint venture with Ascentage Pharma. The UBX1967 License Agreement also grants UNITY the right to continue its preclinical development efforts with respect to another Ascentage Pharma-controlled Bcl-2 inhibitor compound that will serve as a back-up to UBX1967.

About Cellular Senescence and Senolytic Medicines Cellular senescence is a natural biological state in which a cell permanently halts division. Senescent cells accumulate with age and secrete as many as 100 different biologically active proteins, including pro-inflammatory factors, proteases, pro-fibrotic factors and growth factors that disturb the tissue microenvironment. This collection of secreted proteins is referred to as the SASP. In addition to its effects on tissue function, the SASP contains factors that induce senescence in neighboring cells, setting off a cascade of events that culminates in the formation of the functionally aged and/or diseased tissue that appears to underlie a variety of age-related diseases. UNITY believes that the elimination of senescent cells will remove SASP factors—addressing a root cause of diseases of aging. Senolytic medicines, or treatments designed to selectively remove senescent cells, target the SASP at its source, and may have a more durable impact on certain diseases of aging than current therapies.

About UNITY UNITY is developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging. UNITY's initial focus is on creating senolytic medicines to selectively eliminate senescent cells and thereby treat age-related diseases, such as osteoarthritis, eye diseases and pulmonary diseases. More information is available at www.unitybiotechnology.com or follow us on Twitter .

About Ascentage Pharma Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company’s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage Pharma has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. For more information, please visit www.ascentagepharma.com .

Forward-Looking Statements This press release contains forward-looking statements, including but not limited to statements related to the role of cellular senescence in diseases of aging, UNITY’s potential to selectively eliminate senescent cells and thereby treat patients with age-related diseases, and UNITY’s ability to develop and advance product candidates into and successfully complete preclinical studies and clinical trials, including UNITY’s ongoing pre-clinical studies of UBX1967 to support the filing of an IND application in the second half of 2019. Such forward-looking statements involve substantial risks and uncertainties that could cause UNITY’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including UNITY’s early stage of development and its understanding of senescence biology, the clinical trial process, UNITY’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials and pre-clinical studies, and the results of preclinical studies may not be predictive of future results. UNITY undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITY’s most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2018, filed with the Securities and Exchange Commission on November 7, 2018, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Media & Investors Austine Graff 707-593-6151

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Specialized Metal Makers Become the New M&A Prize Again

Updated Category News Views 44

A forgotten heat-treatment line can suddenly be worth more than a shiny new mill when buyers realize nobody can duplicate its certifications, workforce, and customer approvals overnight. That is the basic truth sitting underneath BGL's Nov. 19, 2026 assessment of the U.S. metals market. The easy headline is consolidation. The useful takeaway is much narrower: specialized...

Continue Reading
Bella Rio's Proposed Preferred B Share Giveaway Plan

Updated Category News Views 46

A founder handing over two million of his own common shares is the sort of detail that makes investors stop stirring their coffee. Bella Rio Consulting, the company behind ROCK'N Vodka and Bella Rio Bourbon, says co-founder and Vice President Andy Roiniotis proposes to contribute 2,000,000 personally held Common shares for reclassification into Preferred Series B shares....

Continue Reading
COFE+ Barista Test Puts Robotic Coffee on the Clock

Updated Category News Views 40

A swan latte taking 18 seconds less is not nothing, even if it is hardly a verdict on the future of coffee. COFE+, the seventh-generation robotic barista from Shanghai Hi-Dolphin Robot Technology, beat an award-winning human barista across five drinks at a live November 14 competition in Yiwu. That is a clean, visible demonstration of what machines are increasingly built...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 97

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
UnitedHealth’s CMS Audit Shock Puts Disclosures Under Lens

Updated Category News Views 123

Medicare Advantage's audit bill just landed with a nasty thud. UnitedHealth Group shares fell more than 10% on November 18 after the Centers for Medicare & Medicaid Services proposed new anti-fraud, audit, and repayment rules for the program. For holders of NYSE:UNH, this was not some sleepy policy memo buried in a federal filing cabinet. It was a hard reminder that...

Continue Reading
CATL Builds Türkiye Battery Service Muscle in Istanbul

Updated Category News Views 82

Battery warranties look mighty impressive until a pack needs work on a Tuesday morning and nobody nearby can touch it. CATL's new NING SERVICE Experience Center in Istanbul goes straight at that unglamorous problem. The facility, announced November 19, 2026, is described as Türkiye's first dedicated battery depot repair center and an integrated sales-and-service hub. It...

Continue Reading
AltaPointe PATH Outreach Puts Housing Waits in Focus

Updated Category News Views 128

Two years is a brutal length of time to ask somebody without stable housing to wait for an income-based apartment. That number hangs over AltaPointe Health's PATH program in Mobile, Alabama, and it ought to. The organization helped 16 people secure permanent housing in the past fiscal year, a figure that can look small if somebody is just skimming a report. It looks very...

Continue Reading
CCTV-4 Revisits China's Enduring Academy Tradition

Updated Category News Views 57

Stone courtyards, old books and hard questions are getting prime time on CCTV-4, which is a more interesting programming bet than it may first appear. Enduring Chinese Academies, a ten-episode cultural exploration series from China Media Group's Global Chinese Programming Center, is built around a simple theme: “One academy, one spirit.” It begins airing November 22...

Continue Reading
We Are All Human Gala Puts Latino Leadership Center Stage

Updated Category News Views 31

Recognition can sound like soft stuff until a room full of decision-makers decides whose work deserves the microphone. That was the real point of We Are All Human’s sixth annual Gala at Cipriani Wall Street in New York on Nov. 20, 2026: put Latino leadership, cultural influence and economic contribution in plain view rather than treating them as a decorative footnote....

Continue Reading
Colossal's Halloween Campaign Wins Top Communicator Honor

Updated Category News Views 76

A horror-themed fan competition putting money toward hospitalized children is not the usual awards-season material, which is precisely why Colossal's latest recognition lands with some weight. The Phoenix-based professional fundraiser received an Award of Excellence, the top honor at the 32nd annual Communicator Awards, for its Face of Halloween campaign in the Innovation...

Continue Reading

Top 5 Most Recently Viewed Articles

Westpac's CEO Calls for Enhanced Social Media Fraud Measures

Updated Category News Views 140

Westpac's Urgent Plea for Enhanced Fraud Prevention Westpac Banking Corp's CEO has made a significant call for social media companies, including Meta Platforms, to take a more proactive role in fighting online financial fraud. With an alarming rise in scams targeting consumers, this appeal highlights the urgent need for a united front against fraudulent activities online....

Continue Reading
Empowering Veterans: Bombardier's Commitment to Career Success

Updated Category News Views 170

Empowering Veterans Through Partnership with the Army Today, Bombardier proudly announces its partnership with the U.S. Army via the Partnership for Your Success (PaYS) Program. This initiative is designed to connect service members with valuable civilian career opportunities, ensuring they receive guaranteed job interviews with participating employers. This strategic...

Continue Reading
AWH Faces Market Challenges with Stock at Record Low

Updated Category News Views 107

AWH Stock Experiences Significant Decline AWH stock has recently dropped to a concerning 52-week low of $0.38, reflecting the tough market conditions. The dip in stock price highlights the company’s struggles, with its market capitalization now at a mere $6.5 million. Over the past year, the stock has lost approximately 90.68% of its value, showcasing a substantial...

Continue Reading
Vimeo's Q3 2024 Financial Insights and Future Outlook

Updated Category News Views 370

Vimeo Posts Third Quarter 2024 Financial Update Vimeo recently shared its financial snapshot for the third quarter of 2024, showcasing the company's growth trajectory and key achievements. The shareholder letter is now available on the investor relations section of their website, allowing stakeholders to delve into the details. This transparency is vital for maintaining...

Continue Reading
Implantica's Year-End Report Highlights RefluxStop Progress

Updated Category News Views 165

Implantica's Year-End Report: Driving Forward with Innovation Implantica has made significant strides in the healthcare sector, particularly with its innovative product, RefluxStop™, which aims to transform how gastroesophageal reflux is treated. This year-end report presents a comprehensive overview of the company's achievements for the year. RefluxStop™ FDA...

Continue Reading